Medical XpressAdults 75 and Older Who Stopped Statins Had Similar Three-Year Survival, Trial Finds

⚠️ Small Study / Early Comparative Evidence

The role of statins for primary prevention in older adults remains uncertain because most prevention trials enrolled younger populations. A randomized French study evaluated whether continuing statins provides measurable short-term benefit in adults aged 75 years or older without prior cardiovascular disease.

Clinical Considerations

• 1,160 adults aged 75 years or older were randomized to continue or discontinue statin therapy.
• Three-year mortality was 7.2% after discontinuation versus 7.9% with continuation, with no significant difference reported.
• Major cardiovascular events, including myocardial infarction and stroke, were similar between groups during follow-up.
• Discontinuation produced an approximately 50% increase in LDL cholesterol, rising from 115 mg/dL to 171 mg/dL.

Practice Applications

• Interpret findings within the context of a three-year follow-up period.
• Recognize persistent uncertainty regarding longer-term cardiovascular outcomes.
• Consider individualized shared decision-making when discussing ongoing statin therapy.
• Monitor evolving evidence on primary prevention in older adults.